CA2880021C - Quinone compounds and their uses for the treatment of cancer - Google Patents
Quinone compounds and their uses for the treatment of cancer Download PDFInfo
- Publication number
- CA2880021C CA2880021C CA2880021A CA2880021A CA2880021C CA 2880021 C CA2880021 C CA 2880021C CA 2880021 A CA2880021 A CA 2880021A CA 2880021 A CA2880021 A CA 2880021A CA 2880021 C CA2880021 C CA 2880021C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- treatment
- compound
- diaphorase
- express
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1213486.2 | 2012-07-30 | ||
| GBGB1213486.2A GB201213486D0 (en) | 2012-07-30 | 2012-07-30 | Quinone compounds and their uses for the treatment of cancer |
| PCT/EP2013/065968 WO2014020012A1 (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2880021A1 CA2880021A1 (en) | 2014-02-06 |
| CA2880021C true CA2880021C (en) | 2020-01-14 |
Family
ID=46881339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2880021A Expired - Fee Related CA2880021C (en) | 2012-07-30 | 2013-07-30 | Quinone compounds and their uses for the treatment of cancer |
Country Status (16)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887684B (zh) * | 2022-12-02 | 2025-02-14 | 南京邮电大学 | 基于dna折纸和阿霉素前药构筑的递药纳米体系及方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156744A (en) * | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| WO2006009893A2 (en) * | 2004-06-21 | 2006-01-26 | Hutchison Medipharma Enterprises Limited | Cancer chemotherapy |
| AU2008224962B2 (en) * | 2007-03-13 | 2013-07-25 | Spectrum Pharmaceuticals, Inc. | Intravesical apaziquone administration following transurethral resection for treating cancer |
-
2012
- 2012-07-30 GB GBGB1213486.2A patent/GB201213486D0/en not_active Ceased
-
2013
- 2013-07-30 ES ES13742640.9T patent/ES2662917T3/es active Active
- 2013-07-30 EP EP13742640.9A patent/EP2882743B1/en not_active Not-in-force
- 2013-07-30 GB GB1422799.5A patent/GB2519004B/en not_active Expired - Fee Related
- 2013-07-30 BR BR112015001837-8A patent/BR112015001837B1/pt not_active IP Right Cessation
- 2013-07-30 CN CN201380040388.1A patent/CN104583200B/zh not_active Expired - Fee Related
- 2013-07-30 NO NO13742640A patent/NO2882743T3/no unknown
- 2013-07-30 RU RU2015105036A patent/RU2688675C2/ru not_active IP Right Cessation
- 2013-07-30 DK DK13742640.9T patent/DK2882743T3/en active
- 2013-07-30 JP JP2015524762A patent/JP6317742B2/ja not_active Expired - Fee Related
- 2013-07-30 KR KR1020157002128A patent/KR102142164B1/ko not_active Expired - Fee Related
- 2013-07-30 IN IN1223DEN2015 patent/IN2015DN01223A/en unknown
- 2013-07-30 AU AU2013298653A patent/AU2013298653B2/en not_active Ceased
- 2013-07-30 US US14/418,394 patent/US9266829B2/en not_active Expired - Fee Related
- 2013-07-30 WO PCT/EP2013/065968 patent/WO2014020012A1/en active Application Filing
- 2013-07-30 MX MX2015000969A patent/MX361650B/es active IP Right Grant
- 2013-07-30 CA CA2880021A patent/CA2880021C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013298653B2 (en) | 2017-10-19 |
| MX361650B (es) | 2018-12-13 |
| CN104583200B (zh) | 2017-07-25 |
| BR112015001837B1 (pt) | 2021-11-16 |
| ES2662917T3 (es) | 2018-04-10 |
| KR102142164B1 (ko) | 2020-08-06 |
| BR112015001837A2 (pt) | 2017-07-04 |
| IN2015DN01223A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-06-26 |
| US9266829B2 (en) | 2016-02-23 |
| RU2015105036A (ru) | 2016-09-20 |
| JP6317742B2 (ja) | 2018-04-25 |
| MX2015000969A (es) | 2015-09-23 |
| EP2882743B1 (en) | 2017-12-13 |
| CA2880021A1 (en) | 2014-02-06 |
| DK2882743T3 (en) | 2018-03-12 |
| EP2882743A1 (en) | 2015-06-17 |
| GB2519004A (en) | 2015-04-08 |
| WO2014020012A1 (en) | 2014-02-06 |
| GB201213486D0 (en) | 2012-09-12 |
| US20150210639A1 (en) | 2015-07-30 |
| KR20150036215A (ko) | 2015-04-07 |
| RU2688675C2 (ru) | 2019-05-22 |
| NO2882743T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2018-05-12 |
| JP2015524815A (ja) | 2015-08-27 |
| AU2013298653A1 (en) | 2015-02-19 |
| CN104583200A (zh) | 2015-04-29 |
| GB2519004B (en) | 2016-03-30 |
| HK1209111A1 (zh) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070015814A1 (en) | Parp Modulators and Treatment of Cancer | |
| WO2013033688A1 (en) | Treatment of cancer | |
| EP3837256B1 (en) | Urea compounds and compositions as smarca2/brm-atpase inhibitors | |
| Du et al. | Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo | |
| Jacob Victorino et al. | Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle | |
| JP2013231065A (ja) | 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用 | |
| CA3217111A1 (en) | Use of medicament in treatment of tumor disease | |
| Yao et al. | Direct cellular targets and anticancer mechanisms of the natural product oridonin | |
| CA2880021C (en) | Quinone compounds and their uses for the treatment of cancer | |
| US20150238562A1 (en) | Bourvadin derivatives and therapeutic uses thereof | |
| US20100279964A1 (en) | Angular Pyranocoumarins, Process for Preparation and Uses Thereof | |
| WO2023131305A1 (zh) | Prmt5抑制剂和抗癌治疗剂的组合 | |
| EP3345624A1 (en) | Bouvardin derivatives and therapeutic uses thereof | |
| CN115814095A (zh) | Rad51抑制剂和抗癌治疗剂的组合 | |
| CN116761602A (zh) | Y盒结合蛋白质1抑制剂 | |
| JP2023552368A (ja) | Ｙボックス結合タンパク質１阻害剤 | |
| CN112262005A (zh) | 制备纯化的原子量子簇的方法 | |
| JP2021525705A (ja) | 有機化合物 | |
| EA013117B1 (ru) | Ингибиторы циклинзависимых киназ, относящиеся к ним композиции и применения | |
| US20230181564A1 (en) | Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites | |
| CN102006866B (zh) | 激酶蛋白结合抑制剂 | |
| CN1615127A (zh) | 取代的二环[3.3.1]壬烷－2,4,9三酮作为活性药物成分 | |
| HK40045602B (en) | Urea compounds and compositions as smarca2/brm-atpase inhibitors | |
| HK40045602A (en) | Urea compounds and compositions as smarca2/brm-atpase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170927 |
|
| MKLA | Lapsed |
Effective date: 20210730 |